MedTrace Logo

MyeloGen: Germline Testing for Predisposition to Myeloid Malignancies

NCT06543511 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2024-11-22

No results posted yet for this study

Summary

This research study is evaluating the feasibility of conducting cancer genetic testing using healthy skin cells among participants with a diagnosis of a blood cancer. Additionally, investigators will evaluate how often participants with blood cancers are found to have risk for cancer based on family genes.

Conditions

Interventions

OTHER

Genetic Blood Test

Germline genetic testing using skin fibroblasts

Sponsors & Collaborators

Principal Investigators

  • Christopher Reilly, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-29
Primary Completion
2028-07-01
Completion
2029-07-01

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06543511 on ClinicalTrials.gov